BMP4-GPX4 Pathway Modulation Reduces Ferroptosis and Promotes Retinal Stem Cell Differentiation in Glaucoma Models

Study Background and Research Question

Glaucoma, a leading cause of irreversible blindness, is most commonly characterized by the progressive loss of retinal ganglion cells (RGCs) due to sustained high intraocular pressure (IOP). Recent advances have highlighted ferroptosis—an iron-dependent, oxidative form of programmed cell death—as a significant contributor to RGC degeneration in high IOP glaucoma scenarios (Fang et al., 2025). While retinal stem cell (RSC) transplantation offers promise for restoring retinal function, the survival and functional integration of transplanted RSCs remain limited by the hostile microenvironment driven by oxidative stress and ferroptosis. The present study investigates whether modulating the bone morphogenetic protein 4 (BMP4) and glutathione peroxidase 4 (GPX4) signaling axis can both reduce ferroptosis and enhance RSC differentiation into RGCs, thereby improving the efficacy of cell-based repair in glaucoma.

Key Innovation from the Reference Study

The central innovation in this work is the demonstration that the BMP4-GPX4 pathway can be leveraged to combat ferroptosis and simultaneously promote the differentiation of transplanted RSCs in the context of high IOP glaucoma (Fang et al., 2025). Previous studies have independently implicated BMP4 in neural differentiation and GPX4 in ferroptosis defense. Here, the authors provide mechanistic and functional data showing that BMP4 upregulation leads to increased GPX4 expression, which in turn reduces reactive oxygen species (ROS) and iron accumulation—key drivers of ferroptosis. This coordinated activity not only supports endogenous RGC survival but also enhances the neurogenic potential of exogenous RSCs following transplantation.

Methods and Experimental Design Insights

To investigate the BMP4-GPX4 axis, the researchers established a mouse model of glaucoma using NMDA-induced excitotoxicity, a widely accepted method for simulating RGC injury and oxidative stress (Fang et al., 2025). NMDA (N-Methyl-D-aspartic acid) is a specific NMDA receptor agonist that induces calcium influx and mimics glutamate-mediated excitotoxic injury, thereby modeling the neurodegenerative processes observed in glaucoma. The use of NMDA enables precise control over injury induction and reproducibility across experimental cohorts, consistent with established protocols in excitotoxicity research (internal resource).

The experimental workflow included:

• Induction of glaucoma in mice via intravitreal NMDA injection to model high IOP-associated RGC damage.
• Assessment of RGC injury using immunofluorescence for Brn3a, a selective RGC marker.
• Bioinformatic analysis (KEGG enrichment) of GEO transcriptomic datasets to identify upregulated pathways, with validation by qPCR and Western blot for BMP4 and downstream SMAD signaling mediators.
• Measurement of ferroptosis-associated parameters: ROS (oxidative stress assay), glutathione (GSH), malondialdehyde (MDA, a lipid peroxidation marker), and Fe²⁺ (iron accumulation) in retinal tissue.
• Analysis of ferroptosis marker proteins (ACSL4, GPX4, SLC7A11) by Western blot to quantify changes at the protein level.

This multifaceted approach provides both molecular and functional insight into the interplay between BMP4 signaling, oxidative stress, and ferroptosis in the glaucomatous retina.

Protocol Parameters

• NMDA-induced glaucoma model: Intravitreal injection of NMDA at doses standardized in prior neurodegenerative studies; enables rigorous modeling of RGC damage and oxidative stress.
• Immunofluorescence for RGC quantification: Brn3a staining to reliably assess RGC survival in experimental and control groups.
• qPCR and Western blot validation: Quantitative assessment of BMP4, SMAD1/3/5, GPX4, and ferroptosis markers to confirm pathway activation and phenotype modulation.
• Oxidative stress and ferroptosis assays: Measurement of ROS, GSH, MDA, and Fe²⁺ to provide a comprehensive oxidative stress and iron homeostasis profile.

Core Findings and Why They Matter

The study first confirmed successful RGC injury in the NMDA-induced glaucoma model, as evidenced by reduced Brn3a expression. Transcriptomic and protein analyses showed elevated BMP4 and downstream SMAD signaling in glaucomatous retinas. Functionally, the model exhibited increased ROS, depleted GSH, elevated MDA, and increased Fe²⁺—all hallmarks of ferroptosis.

Upon activation of the BMP4-GPX4 axis, the authors observed:

• Significant reduction in oxidative stress (lower ROS and MDA levels).
• Restoration of GSH, supporting redox balance.
• Reduced iron accumulation, mitigating ferroptotic cell death.
• Increased GPX4 expression, central to ferroptosis defense.
• Enhanced differentiation of transplanted RSCs into mature RGCs, suggesting improved integration and functional rescue potential.

These results collectively demonstrate that BMP4-GPX4 pathway modulation can both protect endogenous RGCs and facilitate successful stem cell-based retinal repair. This dual mechanism offers a robust therapeutic strategy for neuroprotection and regeneration in glaucoma (Fang et al., 2025).

Comparison with Existing Internal Articles

Several internal resources detail the use of NMDA in modeling neuronal injury and oxidative stress, highlighting its role in reproducible excitotoxicity research. For instance, the guide on NMDA in Excitotoxicity Research underscores its utility in both neurodegeneration and stem cell transplantation studies. The article Scenario-Driven Solution further discusses how NMDA (SKU B1624) enables precise modeling of oxidative damage and calcium influx, critical for the study of ferroptosis in neurodegenerative disease models. These resources align with the reference study's methodology, reinforcing the importance of well-characterized NMDA receptor agonists for controlled induction of RGC injury and oxidative stress assay validation.

The internal article on the BMP4-GPX4 axis provides complementary evidence that upregulating GPX4 downstream of BMP4 can mitigate ferroptosis and promote RSC differentiation in glaucoma, mirroring the findings of the reference study. This convergence of evidence across independent research and internal literature strengthens the translational potential of BMP4-GPX4 modulation as a neuroprotective and regenerative strategy.

Limitations and Transferability

While the study employs robust molecular and functional assays, several limitations are noteworthy. First, the reliance on NMDA-induced injury, while highly reproducible, may not capture the full spectrum of chronic pathophysiological changes seen in human glaucoma. Second, the mouse model does not account for potential interspecies differences in RSC behavior or immune-mediated responses following transplantation. Third, while the BMP4-GPX4 axis appears central to the observed protective effects, it is possible that other parallel pathways may also contribute to RGC survival and differentiation, warranting further mechanistic dissection.

Transferability to clinical contexts will require validation in chronic glaucoma models and assessment of long-term safety and efficacy following BMP4-GPX4 modulation and RSC transplantation. Nevertheless, the approach is well-grounded in conserved mechanisms of redox biology and stem cell differentiation, supporting its potential relevance across species and disease models.

Research Support Resources

For researchers aiming to replicate or extend these workflows, NMDA (N-Methyl-D-aspartic acid) (SKU B1624) from APExBIO provides a highly specific and pure NMDA receptor agonist suitable for modeling excitotoxic injury, oxidative stress, and calcium influx in retinal and neurodegenerative disease models. This reagent is widely cited in the literature for its reproducibility and direct receptor-mediated action, making it a foundational tool for both excitotoxicity research and studies of ferroptosis and stem cell transplantation. NMDA is intended for laboratory research use only and should be handled in accordance with best practices for neuropharmacological reagents.